What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2336.png

*Greater improvements at week 16 from baseline compared to placebo were demonstrated in health-related quality of life as measured by the Dermatology Life Quality Index. 1

 

The safety profile in the SUNSHINE and SUNRISE trials is consistent with that already reported, with no new or unexpected safety concerns detected, the study duration is 60 weeks2

Group 2371.png

 

Cosentyx HS LaunchPad 25.12.2023-02 3.png

Adapted from Ref.2

HLGT=high-level group term; HLT=high-level term; MedDRA=medical dictionary for regulatory activities.

You can tailor the dosing based on your patients’ needs1

2373.png
Group 2377.png

Cosentyx API

PDF
View

References

  1. Cosentyx 150,300 mg Egyptian Drug Authority approved leaflet, Approval date: 23-03-2025.

  2. Kimball AB, Jemec GB, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Bourboulis EJ, Villani AP, Schwinn A, Ruëff F. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of twoidentical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. The Lancet. 2023 Mar 4;401(10378):747-61.


Approved by Egyptian Drug Authority: BF0424OA4706/082025. Invalidation date: 28/08/2027. 

Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg

Cosentyx HS QR Code.png

BF0424OA4706/082025

28/08/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting